SensoDetect - Notification of patent granted in the United States

SensoDetect has been informed by AWA Patent that the US Patent Office has granted patent application from SensoDetect regarding "BRAIN RESPONSE STATE".

SensoDetect representative for patents and IPO, AWA patent, is assisting with the patent portfolio, which today consists of 4 families and where BRAINSTEM RESPONSE STATE is one of these. Brainstem response application includes both audio stimuli and the analytical part of which SensoDetects technology is based and is therefore an important part of patent protection. Patents in the United States are valid for 20 years from the date of application.

Briefly about the US market;

ADHD

The appearance of ADHD begins at 7 years of age. According to the National Institute of Mental Health (NIMH), about 4.1% of adults in the United States are affected by ADHD who are 18 years of age and older. Also, about 9.0% of children between 13 and 18 years in the United States are affected by ADHD. Boys have according to US studies four times greater risk than girls.

Schizophrenia

Investigations, clinical diagnostic interviews and records estimates the incidence of schizophrenia in the United States between 0.25 and 0.64 percent. Schizophrenia is characterized by disturbances in thought processes, perceptions, emotional response and social interactions. Schizophrenia is usually diagnosed between 15 and 35 years. Globally, it affects about 1% of the total population.

Autism

According to a recent epidemiological study, it has been observed that about 87% of ASD cases are from Europe, Japan and North America, while only 10% of the world's children live in these countries. Additionally, the Centers for Disease Control (CDC) Autism and Development Disabilities Monitoring (ADDM) community reported that approximately 1 in 68 children in the United States were identified with an autism spectrum disorder (ASD) in 2016.

"The US is a potentially important market for SensoDetect and we have been waiting for patent notification for a while, so it is gratifying that we now have a patent granted. It strengthens the value both to customers and to the company at large. US healthcare is interesting in many ways and this opens up new opportunities.", says CEO, Johan Olson, SensoDetect AB (publ.).
 

Johan Olson

VD, SensoDetect Aktiebolag (publ)

Phone: +46 705 424600

e-mail: jo@sensodetect.com

 

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Our Mission
Improve the lives of people with mental illness
Our Vision
Making ABR profiling tests with SensoDetect technology an integral part of setting diagnosis for mental illness
Our Value Proposition:
SensoDetect provides a complete audiogram for the brainstem, helping health care professional to set psychiatric diagnoses objectively and
cost effectively. This unique offering improves patients’ quality of life and reduces the economic impact on the health care system and society

Tags:

Subscribe

Documents & Links

Quotes

The US is a potentially important market for SensoDetect and we have been waiting for patent notification for a while, so it is gratifying that we now have a patent granted. It strengthens the value both to customers and to the company at large. US healthcare is interesting in many ways and this opens up new opportunities.
CEO, Johan Olson, SensoDetect Ab (publ.)